$Pistol Pete$, $Mick$ & Friends Stock Picks /news, DD and charts

[mick]

COULD DOUBLE NEXT WK. $IBIO

potential next wk & beyond #2 iBio Stock Is Trading Higher After Announcing Next-Gen COVID-19 Vaccine Candidate
Vandana Singh
Fri, May 7, 2021, 4:01 AM·1 min read

https://finance.yahoo.com/news/ibio-stock-trading-higher-announcing-110113853.html

[-chart]s.yimg.com/ny/api/res/1.2/BMQcJJ_iXqdVPZ8ddAfLzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://s.yimg.com/uu/api/res/1.2/I8ba99jCRWs8ZEovIM3Olg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/6f9863940e7c16a73e7bc6c0157539d0[/chart]

https://s.yimg.com/uu/api/res/1.2/I8ba99jCRWs8ZEovIM3Olg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/6f9863940e7c16a73e7bc6c0157539d0">https://s.yimg.com/uu/api/res/1.2/I8ba99jCRWs8ZEovIM3Olg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/6f9863940e7c16a73e7bc6c0157539d0"; />

iBio Inc (NYSE: IBIO) has provided an update on its IBIO-201 program and reported its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection.

IBIO-201 combines antigens derived from the spike protein ("S protein") fused with iBio's patented LicKM booster molecule

It recently completed IND-enabling toxicology studies. No adverse effects at low or high doses were identified.

The Company also reported on the development of IBIO-202, a subunit vaccine candidate that targets the nucleocapsid protein ("N protein") of SARS-CoV-2.

"In light of the successful global roll-out of COVID-19 vaccines targeting the S protein and the emergence of variant strains of the disease, we decided to focus our efforts on the continued development of IBIO-202 as a differentiated vaccine candidate," said Tom Isett, Chairman, and CEO.

iBio has expressed N protein antigens and initiated intramuscular and intranasal preclinical studies to identify favorable antigen-adjuvant combinations using its plant-based FastPharming System.

Results are expected in early Q1 FY2022.

Price Action: IBIO shares are 30.4% at $1.80 during premarket trading on the last check Friday.

See more from Benzinga

Click here for options trades from Benzinga

Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients

Cigna's Strong Performance Across Businesses Drive Q1 Earnings Beat; Raises 2021 Guidance

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Quote Lookup


Symbol Last Price Change % Change
IBIOiBio, Inc. 1.6100 +0.2300 +16.67%
Symbol Last Price Change % Change
ACCRAccess-Power & Co., Inc. 0.0240 +0.0066 +37.93%
AABBAsia Broadband, Inc. 0.1869 +0.0360 +23.81%
FTOCFTAC Olympus Acquisition Corp. 10.08 0.00 0.00%
GOEVWCanoo Holdings Ltd. 1.9100 +0.1200 +6.70%
AGCUUAltimeter Growth Corp. 12.35 -0.05 -0.40%
TRENDING
1.
Citi Defeat on $500 Million Error Was Wrong, Groups Say
2.
UPDATE 1-AstraZeneca weighs seeking full U.S. approval for COVID shot - WSJ
3.
Hertz Says Travel Demand Returning After 33% Revenue Decline
4.
UPDATE 1-CDC says U.S.-bound air travelers can use some self-administered COVID-19 tests
5.
Khan Academy’s Sal Khan on the future of higher education and why it might include non-traditional methods